Related Experiment Video
Updated: Aug 8, 2026
09:32
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
Published on: September 26, 2019
Simulating real-world abrocitinib use in atopic dermatitis: results from JADE REAL
Raj Chovatiya1,2, Matthew Zirwas3,4,5, Melinda J Gooderham6,7,8
1Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA.
The Journal of Dermatological Treatment
|August 7, 2026
Summary
The JADE REAL study provided abrocitinib access for moderate-to-severe atopic dermatitis (AD) patients. Abrocitinib demonstrated rapid improvements in AD severity, supporting clinical decision-making for dose selection and modification.
Area of Science:
- Dermatology
- Clinical Pharmacology
- Real-World Evidence Studies
Background:
- The JADE REAL study was a global, prospective, multicenter, open-label expanded access protocol.
- It integrated clinical trial rigor with real-world management flexibility for atopic dermatitis (AD).
Purpose of the Study:
- To provide access to abrocitinib for patients with moderate-to-severe AD lacking adequate treatment options.
- To assess safety and exploratory efficacy of abrocitinib in a real-world setting.
Main Methods:
- Patients received abrocitinib (100 mg or 200 mg daily) at investigator's discretion.
- Dose adjustments were permitted during treatment.
- Safety and exploratory efficacy endpoints were evaluated.
Main Results:
- 312 patients were included, with initial doses of 100 mg (38.5%) or 200 mg (61.5%).
- Treatment-emergent adverse events (TEAEs) occurred in 78.2% of patients, leading to dose changes in 12.5%.
- Rapid improvements in AD severity were observed up to 72 weeks.
Conclusions:
- Most patients maintained their initial abrocitinib dose.
- Dose reductions were infrequent and often not solely due to TEAEs.
- Findings support clinical decision-making for abrocitinib dose selection and modification in AD management.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...